Frontiers in medicine · 2026
Immunoinformatics-driven multi-epitope vaccine design targeting PSMA, STEAP1, and B7H3 for prostate cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Runtunuwu Stefanus Vicky Bernhard Elisa, Tallei Trina Ekawati, Kim Hyo Jeong, Park Moon Nyeo, Celik Ismail, Kirilmaz Burak, Turalaki Grace Lendawati Amelia, Fatimawali Fatimawali, Tendean Lydia Estelina Naomi, Kaseke Martha Marie, Makawaehe Dionisius Rafael, Rambi Elne Vieke, Kim Bonglee
Аннотация
INTRODUCTION: Prostate cancer remains a major global health challenge, necessitating precision immunotherapeutic strategies tailored to tumor-associated antigens. This study aimed to design a multi-epitope peptide vaccine targeting prostate-specific membrane antigen (PSMA), six-transmembrane epithelial antigen of prostate 1 (STEAP1), and B7-H3, three biomarkers strongly associated with prostate cancer progression.
METHODS: A multi-layered immunoinformatics-driven approach was employed, integrating epitope prediction, antigenicity and immunogenicity assessment, allergenicity and toxicity screening, population coverage analysis, molecular docking, and molecular dynamics simulations. Selected epitopes were assembled into a vaccine construct using appropriate adjuvants and linkers to enhance immune activation and structural stability.
RESULTS: The designed vaccine construct demonstrated extensive global HLA allele coverage (97.51%), strong binding affinity to B-cell receptors, MHC molecules, and favorable structural stability during molecular dynamics simulations.
DISCUSSION: These findings suggest that the proposed multi-epitope vaccine represents a promising immunotherapeutic candidate for prostate cancer and warrants further experimental validation.
METHODS: A multi-layered immunoinformatics-driven approach was employed, integrating epitope prediction, antigenicity and immunogenicity assessment, allergenicity and toxicity screening, population coverage analysis, molecular docking, and molecular dynamics simulations. Selected epitopes were assembled into a vaccine construct using appropriate adjuvants and linkers to enhance immune activation and structural stability.
RESULTS: The designed vaccine construct demonstrated extensive global HLA allele coverage (97.51%), strong binding affinity to B-cell receptors, MHC molecules, and favorable structural stability during molecular dynamics simulations.
DISCUSSION: These findings suggest that the proposed multi-epitope vaccine represents a promising immunotherapeutic candidate for prostate cancer and warrants further experimental validation.